T1	Participants 245 333	patients with metastatic breast cancer (MBC) who had previously received anthracyclines.
T2	Participants 357 378	total of 210 patients
T3	Participants 797 916	204 patients evaluable for response assessment, the response rates were 48.6% for GP1, 52.2% for GP2, and 52.3% for GD.
T4	Participants 1108 1141	208 patients evaluable for safety
